The unopened plate should be stored at 2°C to 8°C,The expiry date of the plate is 12 months. Once opened, place unused plates in a resealable bag with desiccant and store at 2°C to 8°C, The shelf life is 1 month from the date of opening.
Your experiment will include 5 simple steps:
a) Add your Biotinylated sample to the plate, incubation for 1 hour and wash the plate.
b) Add your sample to the plate, incubation for 1 hour and wash the plate.
c) Add a diluted Detection antibody to the plate and incubation.
d) Wash the plate and next add TMB or other colorimetric HRP substrate.
e) Stop the substrate reaction by add diluted acid, and Read OD at 450 nm, the OD Value reflects the amount of antibody bound.
Immobilized Biotinylated Human CD19 (20-291), His,Avitag (Cat. No. CD9-H82E9) at 1 μg/mL (100 μL/well) on Streptavidin Coated Plates, Clear, 96-Well (Cat. No. SP-11), can bind Anti-FMC63 antibody with a linear range of 0.1-3 ng/mL (QC tested).
Immobilized Biotinylated Human PD-1, Fc,Avitag,His Tag (Cat. No. PD1-H82F4) at 1 μg/mL (100 μL/well) on Streptavidin Coated Plates, Clear, 96-Well (Cat. No. SP-11), can bind Human PD-L1, mFc Tag with a linear range of 0.4-6.25 ng/mL (QC tested).
Immobilized Biotinylated Human CD20 Full Length, His,Avitag (HEK293) (Cat. No. CD0-H82E5) at 1 μg/mL (100 μL/well) on Streptavidin Coated Plates, Clear, 96-Well (Cat. No. SP-11), can bind Rituximab with a linear range of 78-625 ng/mL (QC tested).
Immobilized Biotinylated Human FCGRT&B2M Heterodimer Protein, His,Avitag (Cat. No. FCM-H82W7) at 1 μg/mL (100 μL/well) on Streptavidin Coated Plates, Clear, 96-Well (Cat. No. SP-11), can bind Ipilimumab with a linear range of 78-1250 ng/mL (QC tested).
Price(USD) : $30.00
Price(USD) : $130.00
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
This web search service is supported by Google Inc.